Teva fails to get US antitrust class action over alleged asthma inhaler scheme thrown out
Teva Pharmaceuticals was unable to convince a US judge to entirely dismiss antitrust allegations that the company conspired to delay generic competition to its prescription asthma treatment products QVAR and QVAR...To view the full article, register now.
Already a subscriber? Click here to view full article